University of Pittsburgh reports successful COVID-19 vaccine trial

As governments the world over frantically look for a treatment for COVID-19, researchers at the University of Pittsburgh's School of Medicine have announced a potential vaccine against SARS-CoV-2, the new coronavirus causing the COVID-19 pandemic, after successful animal tests.

When tested in mice, the vaccine -- delivered through a fingertip-sized patch -- produced antibodies specific to SARS-CoV-2 at quantities thought to be sufficient for neutralizing the virus, said the team in a paper appeared on eBioMedicine which is published by The Lancet.

The authors are in the process of applying for an investigational new drug (IND) approval from the US Food and Drug Administration (FDA) in anticipation of starting a phase I human clinical trial in the next few months.

If succesful after human trials, the vaccine will still take more than a year to reach the market.

The team had previous experience on SARS-CoV in 2003 and MERS-CoV in 2014.

"These two viruses, which are closely related to SARS-CoV-2, teach us that a particular protein, called a spike protein, is important for inducing immunity against the virus. We knew exactly where to fight this new virus," said co-senior author Andrea Gambotto, associate professor of surgery at the Pitt School of Medicine.

"Our ability to rapidly develop this vaccine was a result of scientists with expertise in diverse areas of research working together with a common goal," added study co-senior author Louis Falo, professor and chair of dermatology at Pitt's School of Medicine and UPMC.

Compared to the experimental mRNA vaccine candidate that just entered clinical trials, the vaccine called "PittCoVacc" (short for Pittsburgh CoronaVirus Vaccine) follows a more established approach, using lab-made pieces of viral protein to build immunity.

When tested in mice, PittCoVacc generated a surge of antibodies against SARS-CoV-2 within two weeks of the microneedle prick.
The researchers used a novel approach to deliver the drug, called a microneedle array, to increase potency.

This array is a fingertip-sized patch of 400 tiny needles that delivers the spike protein pieces into the skin, where the immune reaction is strongest.

The patch goes on like a Band-Aid and then the needles - which are made entirely of sugar and the protein pieces - simply dissolve into the skin.

"We developed this to build on the original scratch method used to deliver the smallpox vaccine to the skin, but as a high-tech version that is more efficient and reproducible patient to patient," Falo said.

The system is also highly scalable, said researchers.
Mass-producing the microneedle array involves spinning down the protein-sugar mixture into a mold using a centrifuge.

Once manufactured, the vaccine can sit at room temperature until it's needed, eliminating the need for refrigeration during transport or storage.

"For most vaccines, you don't need to address scalability to begin with," Gambotto said. "But when you try to develop a vaccine quickly against a pandemic that's the first requirement."

The researchers point out that mice who got their MERS-CoV vaccine produced a sufficient level of antibodies to neutralize the virus for at least a year, and so far the antibody levels of the SARS-CoV-2 vaccinated animals seem to be following the same trend.

Importantly, the SARS-CoV-2 microneedle vaccine maintains its potency even after being thoroughly sterilized with gamma radiation - a key step toward making a product that's suitable for use in humans.

"Testing in patients would typically require at least a year and probably longer," Falo said.

"This particular situation is different from anything we've ever seen, so we don't know how long the clinical development process will take. Recently announced revisions to the normal processes suggest we may be able to advance this faster," the authors wrote.

It is the first study to be published after critique from fellow scientists at outside institutions that describes a candidate vaccine for COVID-19. IANS